Progression of Philadelphia-negative myeloproliferative (MPN) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) to acute myeloid leukemia (AML) is an adverse event in the course of the disease. Although allogeneic hematopoietic SCT (allo-SCT) is considered as the only curative therapy, few data exist on the outcome of patients with Philadelphia-negative MPN or MDS/MPN in blast phase who received an allo-SCT. Sixty patients were included in this retrospective study. AML was secondary to an MPN in 43 cases, whereas AML evolved from an MDS/MPN in 17 cases. Patients received allo-SCT in CR or advanced disease in 26 cases and 34 cases, respectively. With a median follow-up of 31 months (range, 25-44), OS and leukemia-free survival (LFS) were, respectively, 18% and 9% at 3 years. CR at transplant was associated with an improved LFS in univariate and multivariate analysis. The 3-year LFS was 18% for patients undergoing allo-SCT in CR versus 3% in advanced disease (P = 0.008). Absence of thrombosis and an intermediate or favorable AML karyotype were associated with an improved outcome for patients who received allo-SCT in CR. New strategies are needed to improve the outcome of patients with MPN-MDS/MPN in blast phase.
INTRODUCTION
Progression of Philadelphia-negative myeloproliferative or myelodysplastic/myeloproliferative neoplasms (MPN-MDS/MPN) to AML is an adverse event in the course of the disease. This transformation may be related either to the natural history of the disease or to treatments such as alkylators or radioactive phosphorous. 1 This blast phase portends a dismal prognosis with median OS not exceeding a few months. [2] [3] [4] Various strategies have been attempted in order to improve these patients' outcomes, ranging from intensive chemotherapy to less-intensive hypomethylating agents. However, in all cases CR rates remain o 50%. 2, 3, 5 Importantly, patients who achieve CR will ultimately relapse unless they receive allogeneic hematopoietic SCT (allo-SCT). 2, 6, 7 However, such reports are rare and often include small cohorts. 2, [6] [7] [8] [9] [10] The aim of this study was to retrospectively investigate the outcome of patients in blast phase of an MPN-MDS/MPN who received allo-SCT.
PATIENTS AND METHODS

Inclusion criteria
This was a retrospective and multicenter study of the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) (participating centers listed in supplemental data). Selection criteria included (i) adult patients (ii) with a former diagnosis of an MPN-MDS/MPN (iii) who progressed to AML (iv) and who underwent a first allo-SCT between 2000 and 2010, (v) irrespective of stem cell source, conditioning regimen or donor type. Exclusion criteria included (i) the presence of the Philadephia chromosome on karyotype or the detection of the bcr-abl transcript in blood or bone marrow, (ii) a former myelodysplastic syndrome, (iii) MPN-MDS/MPN witho20% blasts in blood/bone marrow. Bcr-abl detection and karyotype were systematically performed at the time of diagnosis to exclude CML. Depending on the time of MPN-MDS/MPN diagnosis, criteria for MPN-MDS/MPN were derived either from the WHO 2001 or WHO 2008 classification. 11, 12 The presence of ⩾ 20% blasts in blood, bone marrow aspirate or biopsy was mandatory to establish AML diagnosis. The study was approved by the scientific council of the SFGM-TC and performed according to the principles of the Declaration of Helsinki.
MPN-MDS/MPN, AML and allo-SCT characteristics
MPN-MDS/MPN characteristics at diagnosis-date, type of MPN-MDS/ MPN and JAK2 status-were reported by SFGM-TC centers. Thrombotic events before or during the course of the MPN-MDS/MPN were defined as any arterial thrombosis-including myocardial infarction or ischemic stroke-or deep venous thrombosis including abdominal thrombosis or pulmonary embolism. Use of alkylating agents or radioactive phosphorus during the course of the MPN-MDS/MPN was also reported.
AML characteristics at diagnosis-including date, FAB classification, WBC count and AML karyotype-were collected. Karyotype was classified according to Grimwade et al. 13 Intensive chemotherapy was defined as any regimen with a theoretical toxicity assumed to be similar to the conventional anthracyclin-cytarabine 3+7 induction combination.
14 Allo-SCT date and characteristics were extracted from the SFGM-TC registry. Disease status at allo-SCT was classified according to standard AML criteria response.
14 Partial response, resistant disease and relapse were categorized as advanced disease.
Statistical analysis
All time related data were measured from the time of allo-SCT unless otherwise specified. OS and leukemia-free survival (LFS) were estimated using the Kaplan-Meier method. 15 Comparisons between subgroups were assessed by the Log-Rank test. 15 The multivariate analysis was performed using a Cox proportional hazards model including all variables with a P-value o0.10 in the univariate analysis. Relapse incidence and TRM were evaluated using the cumulative incidence method and subgroups were compared using the Gray Test. 16 All data were computed using the R package (R Development Core Team, 2006. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org). Table 1 . Overall, 60 patients were included in this study. In 43 cases, AML was secondary to an MPN including polycythemia vera (n = 10), essential thrombocytemia (n = 20) or primary myelofibrosis (n = 8). Some patients could be exposed to hydroxyurea at the time of AML diagnosis. Includes Cy (50 mg/kg)-TBI (6 Gys) (n = 2), aracytine-fludarabineidarubicin (n = 1).
RESULTS
MPN-MDS/MPN and AML characteristics MPN-MDS/MPN characteristics are described in
b Includes amsacrine-aracytine-BU-Cy-fludarabine-ATG (n = 2), Aracytine-BU-Cy-ATG-clofarabine (n = 2), aracytine-fludarabineidarubicine-BU-ATG (n = 1).
patients (78%) received intensive chemotherapy. Three patients received a hypomethylating agent, whereas three patients received both intensive chemotherapy and a hypomethylating agent. Seven patients underwent up-front allo-SCT (Table 2) .
Allo-SCT characteristics Allo-SCT characteristics are described in Table 3 . Median age at time of allo-SCT was 57 (range, 30-68). Patients underwent allo-SCT in first CR (CR1), second CR (CR2) or advanced disease in 22 (37%), 4 (7%) and 34 (57%) cases, respectively. Conditioning regimen was myeloablative for 14 patients (23%), or reducedintensity for 46 patients (77%) including 13 so-called sequential regimens combining a cytoreduction phase followed by conditioning (Table 3) . Donor type was an identical sibling for 23 patients (38%), a 10/10 matched unrelated donor for 21 patients (35%) and a mismatched unrelated donor for 16 patients (27%). In all, 44 patients (73%) received GCSF-mobilized PBSC, whereas 10 patients (17%) and 6 patients (10%) were transplanted with unmanipulated BM or unrelated umbilical cord blood (CB) cells, respectively. Patients did not receive any JAK2 inhibitor during the post-transplant period.
Patients' outcome Engraftment was achieved in 55 patients (92%). With a median follow-up of 31 months (range, 25-44) among surviving patients, OS and LFS were 18% and 9% at 3 years, respectively (Figure 1) . The 3-year cumulative incidence of TRM was 22% (95% CI, 12-34%), whereas the 3-year cumulative incidence of relapse was 68% (95% CI, 54-79) (Figure 1) . In univariate analysis, CR at allo-SCT was the only variable significantly associated with an improved LFS (Table 4 ). In multivariate analysis including patient gender, disease status at allo-SCT and intensity of the conditioning regimen, disease status remained the only significant prognostic factor associated with an improved outcome ( Table 5) .
The 3-year LFS of patients allografted in CR (n = 26) was 18%, whereas the 3-year LFS of patients allografted in advanced disease was only 3% (n = 34) (P = 0.008) (Figure 2 , Table 6 ). Patients who received allo-SCT in CR displayed a 3-year relapse incidence of 61% and a 3-year TRM of 20%. Of note, CR patients with a previous thrombotic event displayed an adverse outcome (3-year LFS of 0% versus 24%, P = 0.02). Similarly, CR patients with an adverse karyotype at the time of AML diagnosis exhibited a poorer outcome (3-year LFS of 10 versus 33% for intermediate or good prognosis, P = 0.03). In advanced disease, the 3-year relapse incidence was 73%, while TRM was 23%. Neither up-front allo-SCT nor sequential regimens brought any benefit (3-year LFS of 0%, median LFS of 2 and 4 months, respectively).
DISCUSSION
Blast phase is a highly adverse event in the course of Philadelphianegative MPN with a median OS of 5 months. 2, 17 Similarly, transformation of chronic myelomonocytic leukemia-the most frequent MPN/MDS-into AML portends poor prognosis with a median OS of~6 months. 4 In MPN, neither intensive chemotherapy nor hypomethylating agents can allow long-term LFS unless allo-SCT is performed. 2, 7 As blast phase occurs most of the time in elderly patients with potential comorbidities such as thrombotic events, few patients can proceed to allo-SCT.
2 Thus, the current cohort likely represents a selected group of patients who were deemed to be eligible to allo-SCT. Nevertheless, outcome was poor in our study despite allo-SCT. Although most MPN evolve to AML through a myelofibrosis step, engraftment was not a major concern and could be achieved in the majority of patients (>90%). 9, 18 Moreover, TRM was relatively moderate,~22%, suggesting the feasibility of the procedure. The main cause for the poor outcome in our study was a high incidence of relapse. Twothirds of patients ultimately relapsed, which underlines the aggressiveness of the blast phase.
In accordance with published data, disease status was a crucial prognostic factor for LFS, with a better outcome for patients transplanted in CR compared with patients grafted in advanced disease. 2, 6, 10 Patients transplanted in advanced disease displayed a dismal outcome (3-year LFS o5%) despite allo-SCT. Most importantly, up-front allo-SCT or sequential regimens did not provide any long-term remission. Whenever possible, patients with a newly diagnosed blast phase should therefore receive chemotherapy to achieve CR before allo-SCT rather than upfront allo-SCT. The outcome remained also quite poor for CR patients with a 3-year LFS of 18% and a high relapse incidence of 61%. Post-allograft strategies are therefore needed to circumvent early AML relapse and to allow time for the graft versus leukemia effect. The use of a hypomethylating agent after allo-SCT warrants further studies as it combines the added value of being an immunomodulatory agent that can exert an anti-leukemic effect.
Similarly, the post-allograft use of anti-JAK2 may decrease relapse incidence and improve LFS. 19 Notwithstanding, a subpopulation of patients who received allo-SCT in CR could benefit from allo-SCT and enjoy a long-term LFS. A graft-versus leukemia effect could be achieved for these patients. Evaluating patients' comorbidities is of high importance when evaluating the need for allo-SCT. The use of alkylating agents that are associated with an increased risk of AML transformation did not seem to impact the outcome of patients. Whether the use of JAK2 inhibitors during the course of MPN may impact allo-SCT outcome remains to be determined. Although our cohort was not large enough to determine the impact of specific MPN-MDS/MPN diseases, LFS was not significantly different for blast phase of MPN compared with blast phase of MPN-MDS. On the contrary, the advent of a thrombotic event before or in the course of MPN-MDS/MPN was associated with an adverse outcome for patients transplanted in CR. AML karyotype was also a significant prognostic factor for patients allografted in CR. CR patients with an intermediate or favorable AML karyotype displayed an improved outcome with a 3-year LFS of 33%. A recent study proposed new criteria for evaluating patients with MPN in blast phase, which included the evaluation of both MPN and AML. 20, 21 Although these criteria have not been validated in large studies yet, they may refine prognostic factors of MPN in blast phase before allo-SCT.
In conclusion, this study suggests that allo-SCT might be proposed for MPN-MDS/MPN patients in blastic transformation preferentially when they could achieve CR. Absence of thrombosis and an intermediate or favorable AML karyotype were associated with an improved outcome for patients in CR. For patients not achieving CR, there is a need to develop innovative strategies in the setting of a clinical trial.
